News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
13
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
495
|
|
Created
|
09/10/04
|
Type
|
Free
|
| Moderators | |||
TA RESOURCES
http://stockcharts.com/h-sc/ui?s=advr
Added to Naked Short list 10/29/08
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=advr
Top Institutional Holders
http://data.cnbc.com/quotes/ADVR/tab/8
Transfer Agent:
http://www.amstock.com/main/
Advanced Viral Research
ADVR
INVESTMENT OVERVIEW
Letter From the CEO
http://www.adviral.com/press_releases/CEO_Letter.pdf
NEWS and EVENTS:
http://www.adviral.com/news.htm
PROFILE
Advanced Viral Research Corp. (OTCBB: ADVR) is a biopharmaceutical company committed to researching, developing and bringing to market new therapies for viral and other diseases. Founded in 1984, the Company has headquarters in Yonkers, New York. The 17,650 square foot facility also includes research laboratory facilities, quality control/quality assurance laboratories, and a production facility designed to produce AVR118 to cGMP standards.
back to top
KEY PRODUCT
Advanced Viral’s principal pharmaceutical product, AVR118, represents a biopolymer chemistry that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs, including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment of cancers, and the body wasting (cachexia) that is a frequent complication of cancers and AIDS.
SIZE OF KEY POTENTIAL MARKETS
• AIDS “Salvage” Therapy - The Centers for Disease Control and Prevention (CDC) estimate a prevalence of 850,000 to 950,000 patients in the U.S. with HIV infection. The CDC further estimate that approximately 40,000 persons are newly infected with HIV each year in the U.S. and that there were 15,245 AIDS related deaths in the U.S. in 2000. The National Institutes of Health (NIH) estimates that 40 million people worldwide were living with HIV/AIDS at the end of 2001.
• Solid Tumors - The American Cancer Society estimates that female breast, colorectal, lung and bronchus, prostate and urinary bladder cancers will account for a total of 766,700 new cases of solid tumors and 281,300 deaths in the U.S. in the year 2002.
•Leukemia/Lymphomas - The American Cancer Society estimates that 60,900 new cases of lymphoma will occur in the U.S. in the year 2002, comprising 7,000 cases of Hodgkin's disease and 53,900 cases of non-Hodgkin's lymphoma. These cancers are estimated to cause a total of 25,800 deaths in the U.S. in the year 2002. It is estimated that 30,800 new cases of leukemia will occur in the U.S. in 2002 and that 21,700 patients will die with leukemia in 2002.
• Genital Warts (HPV infection) – The CDC currently reports an estimated 5.5 Million new cases of HPV each year and an estimated 20 million people in the U.S. are currently infected. Certain strains of HPV cause cervical dysplasia and cervical cancer.
back to top
AVR118 PATENTS
ADVR holds a patent on the preparation of a therapeutic composition of AVR118, and has nine other patents related to AVR118. The Company also has applications for approximately 20 additional patents related to AVR118, and continues to submit applications for additional patents as appropriate.
back to top
CLINICAL TRIALS
• AVR118 is the subject of Phase I/II clinical trials at the Chaim Sheba Medical Center, Israel, in patients who have failed highly active anti-retroviral therapy (HAART) treatment and require salvage therapy.
PRODUCT UNDER PHASE IIb TRIAL
AVR123 is a topical formulation of ARV118 which is currently being investigated for the systemic treatment of cancer related clinical cachexia. This compound has well-documented anti-inflammatory and wound healing activities. Results of a Phase I, open label, dose-escalating study indicated that topical AVR123 is well-tolerated, showing no dose-limiting toxicities. Initial observations of accelerated wound healing in a pig study at the University of Miami suggest that AVR123 may represent an important advance in the management of wounds.
The Phase IIb trial is being conducted at the Friedrich Alexander University Hospital in Erlangen Germany, led by Eckhart Kampgen, M.D., Associate Professor for Strategies of Cellular Immunotherapy at the Department of Dermatology. Dr. Kampgen is leading the Immunomonitoring, RNA and Melanoma Division at the hospital. He has over 80 peer-reviewed publications and has participated as Principal Investigator or Sub-Investigator in more than 20 Phase I, II and III clinical studies since 1995.
BOARD OF DIRECTORS
Advanced Viral Research Corp. Board of Directors brings extensive experience in corporate leadership, business management, corporate law and entrepreneurship to the Company. The ADVR Board of Directors are: Eli Wilner, Chairman; Angelo S. Botter, Stephen M. Elliston, Roy S. Walzer , founder, private investment firm Litchfield Partners, Ltd. and Litchfield Partners I
Eli Wilner, age 50, joined the Board of Directors in December 2001, was elected Chairman of the Board in May 2002. Mr. Wilner brings strong entrepreneurial and business management experience to the Company. He is Founder and Chief Executive Officer of Eli Wilner & Company, a New York City-based art gallery and one of the world’s largest resource for antique American and European frames. Mr. Wilner currently holds a greater than 1% ownership interest in the following technology and biopharmaceutical companies: Biofem, Chronix, ION, Pararllel Communications. He was a member of the Board of Touchpoint Software Company from 1999-2001, and during his tenure approximately 50% of Touchpoint was acquired by WebMD. A published authority in the art world, Mr. Wilner has brought his expertise to the White House and as a member of various art societies around the nation.
Angelo S. Botter joined the Board of Directors in June 2006. His career spanned 37 years in the Pharmaceutical/Healthcare industry with several large multi-national healthcare corporations, including Bristol Labs, Baxter, Lederle, Nordic (Marion Labs) and Abbott Laboratories. Mr. Botter brings Sales, Marketing, Business Development and General Management experience to the Board, having served as General Manager for Abbott in both South Africa and the Netherlands, and Senior Executive Director Pharmaceutical Products for Abbott Canada. His product development and launch experience crosses all major therapeutic categories. Mr. Botter is an inaugural Member in "The Canadian Pharmaceutical Marketing Hall of Fame" and is well known and respected throughout the pharmaceutical community.
Stephen M. Elliston joined Advanced Viral Research Corp. on May 15, 2006 as President and Chief Executive Officer. With over 25 years experience within the biopharmaceutical industry Mr. Elliston brings a wealth of experience to the company in virtually every facet of the business. During the course of his career he has held senior managerial positions in companies such as Schering-Plough, Lederle, Abbott Labs and Burroughs-Wellcome. In addition Mr. Elliston also served as President and CEO of Micrologix Biotech, a publicly traded company based in Vancouver Canada. In this capacity he built a fully integrated R&D company based upon an early stage technology he had in-licensed from the University of British Columbia . Subsequent to this he also played an integral role in the early stage development of Merix Bioscience (now Argos Therapeutics), a Durham, North Carolina based company with a primary focus in the field of therapeutic cancer vaccines.
Roy S. Walzer was named to the Board of Directors in June 2002 and brings investment and venture capital expertise to the Board. Mr. Walzer founded the private investment firm Litchfield Partners, Ltd. in 1987 and founded Litchfield Partners I in 1999, which invests in pharmaceuticals, biotech and technology companies. Prior to founding Litchfield Partners, Mr. Walzer served as Executive Vice President and General Counsel with Sealy Connecticut from 1976 to 1986. He served with the law firm of Carmody and Torrance from 1973 to 1975. Mr. Walzer serves on the Board of Directors of portfolio companies in which Litchfield Partners and Litchfield Partners I are invested.
SCIENCE ADVISORY BOARD
The ADVR Science Advisory Board includes: Dr. George Canellos (Harvard Medical School and Dana Farber Cancer Institute); Dr. James D’Olimpio (North Shore University Hospital and NYU School of Medicine); Dr. Michael Harris (Tomorrow's Children’s Institute for Cancer and Blood Disorders and UMDNJ-New Jersey Medical School); and Dr. Sidney Pestka (Professor and Chairman of the Department of Molecular Genetics, Microbiology and Immunology at Robert Wood Johnson Medical School of the University of Medicine and Dentistry of New Jersey and is chairman and chief scientific officer of PBL Biomedical Laboratories, Piscataway, New Jersey)
